RVXCF News and Press, Resverlogix Corp From 06/29/23

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants") will be amended. Commencing on July 17, 2023, the exercise price of 24,508,489 Warrants (curr...

Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members until...

Calgary, Alberta--(Newsfile Corp. - June 12, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced a peer-reviewed article, entitled, " Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment, " by Dr. Dean...

Calgary, Alberta--(Newsfile Corp. - March 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that it has closed a one-year extension of Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"),...

Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled " Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron varia...

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVI...

NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10 th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW ...

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald McCaffrey, President & CEO will present live at VirtualInvestorConferences.com on March 10 ...

NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...